Navigation Links
Nile Therapeutics Announces Dosing of First Patient in Phase I Study of Cenderitide
Date:5/3/2011

SAN MATEO, Calif., May 3, 2011 /PRNewswire/ -- Nile Therapeutics, Inc. (Nasdaq: NLTX), a biopharmaceutical company that develops novel therapeutics for heart failure patients, today announced dosing of the first patient in a Phase I clinical trial investigating the use of subcutaneous cenderitide.  The trial is being conducted pursuant to Nile's previously announced collaboration with Medtronic and is the first clinical step towards developing cenderitide as a treatment for the post-acute heart failure space, a strategy which was recently granted Fast Track status by the United States Food and Drug Administration (FDA).

"This clinical trial signals the beginning of a new paradigm in the development of therapies for heart failure patients," said James Young, MD Professor and Executive Dean, Cleveland Clinic Lerner College of Medicine. "Administration of cenderitide on an outpatient basis could change how heart failure patients are treated and has the potential to reduce re-hospitalizations by targeting multiple aspects of the heart failure disease process."

The Phase I clinical trial is a placebo-controlled study designed to evaluate pharmacokinetic and pharmacodynamic actions of cenderitide when administered to chronic heart failure patients as a subcutaneous infusion or as a subcutaneous bolus injection. In the first part of the trial, patients will receive two subcutaneous bolus injections of cenderitide.  In the second part of the trial, patients will receive either a 24 hour continuous infusion of cenderitide or placebo, delivered through Medtronic's subcutaneous pump technology. The primary purpose of the trial is to understand the doses required to achieve pre-determined plasma levels of cenderitide delivered through a subcutaneous infusion pump and the pharmacodynamic activity at these doses.

"This clinical trial is a key first step in our post
'/>"/>

SOURCE Nile Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
3. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
4. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
5. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
6. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
7. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
8. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
9. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
10. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
11. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014  Celsion Corporation (the "Company") ... it has received commitments from institutional investors to ... the Company,s common stock in an at-the-market registered ... fund. The Company entered into definitive ... the Company agreed to sell an aggregate of ...
(Date:1/15/2014)... Shire plc (LSE: SHP, NASDAQ: SHPG ... Trading (OFT) approval condition to the announced tender offer for ...   As a result of the waiver, the ... expects to complete the tender offer on January 24, 2014 ... of all of the remaining conditions to the tender offer. ...
(Date:1/15/2014)... 15, 2014 BreedIT Corp (OTC: ... worldwide distributor of highly sophisticated agro-breeding solutions for plant ... 2014, the Company,s board of directors appointed chemistry and ... its new member of the board. From ... Teva Pharmaceutical Industries Ltd (NYSE: TEVA ) ...
Breaking Medicine Technology:Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3
... , RIDGEFIELD, Conn., Aug. 25 Results of ... Warfarin, Compared to Dabigatran)(1) study will be presented at the ... Aug. 30. The primary objective of RE-LY was to ... thrombin inhibitor, dabigatran etexilate, against the current standard therapy, warfarin, ...
... August 25 20% of parents seek medical,help because ... baby,and the accompanying discomfort (crying). Reputed medical journal "Archives,of ... recently,published the results of the clinical research project that ... department of the Brussels,University Hospital. , ...
Cached Medicine Technology:Data From Largest Stroke Prevention Trial in Atrial Fibrillation To Premiere at European Society of Cardiology Congress 2Data From Largest Stroke Prevention Trial in Atrial Fibrillation To Premiere at European Society of Cardiology Congress 3Data From Largest Stroke Prevention Trial in Atrial Fibrillation To Premiere at European Society of Cardiology Congress 4Data From Largest Stroke Prevention Trial in Atrial Fibrillation To Premiere at European Society of Cardiology Congress 5Data From Largest Stroke Prevention Trial in Atrial Fibrillation To Premiere at European Society of Cardiology Congress 6Data From Largest Stroke Prevention Trial in Atrial Fibrillation To Premiere at European Society of Cardiology Congress 7Medical World Recognises New Therapy for Reflux Babies 2
(Date:4/14/2014)... centers around the world, many people live and work ... that block sunlight. And as the global population continues ... darkness will only spread. , To alleviate the ... that redirects sunlight onto narrow streets and alleyways. The ... edge at an angle, where it spreads sunlight onto ...
(Date:4/14/2014)... associate professor of chemical engineering at Virginia Tech ... efficiently analyze living cells. The long-term goal is to ... , In his lab , Lu and his ... molecular events inside cells. These devices promote high sensitivity ... of cells. , Based on their record of achievements, ...
(Date:4/14/2014)... April 2014, Perth, Australia. Drug discovery company Proteomics ... development of a companion diagnostic (CDx) test with ... , The research team authenticated the panel of ... control samples. Seven biomarkers were validated at high ... , The mass spectrometry data was then cross-validated ...
(Date:4/14/2014)... guidelines for high-risk bladder cancer, chemotherapy before or ... clinical practice. The findings are published early online ... the American Cancer Society. , Clinical trials have ... muscle-invasive bladder cancer who are given chemotherapy before ... after surgery also improves survival. To investigate the ...
(Date:4/11/2014)... insights into the processes that control brain cell production ... and other brain-related disorders. , Scientists have gained new ... that controls how and when nerve and brain cells ... to develop and keeps it healthy. Their findings could ... of control, which is a fundamental characteristic of many ...
Breaking Medicine News(10 mins):Health News:Let the sun shine in: Redirecting sunlight to urban alleyways 2Health News:Efficient analysis of small quantity of cells improves chances to understand disease 2
... HealthDay Reporter , THURSDAY, Sept. 16 (HealthDay News) -- ... cancer, new research finds. Prior research has shown higher ... this study is among the first to show that lower ... as gastrointestinal bleeding -- may also be effective, said Eric ...
... of fertilizer that feeds breast cancer progression, significantly ... researchers at UCLA,s Jonsson Comprehensive Cancer Center have ... the immune cells that are trying to fight ... the body against disease into aiders and abettors. ...
... By Amanda Gardner HealthDay Reporter , WEDNESDAY, ... Wednesday over whether the diet drug Meridia should be pulled ... risk of heart attack and stroke. Members of an ... said the drug should remain available to consumers called for ...
... Reporter , WEDNESDAY, Sept. 15 (HealthDay News) -- Children with ... that is, yawn in response to seeing others yawn, a ... contagion," an unconscious response that reflects a recognition of how ... and others is an important step in a child,s social ...
... WEDNESDAY, Sept. 15 (HealthDay News) -- When people with chronic ... the level of hemoglobin cells in their blood should go ... levels don,t increase by much, these "poor responders" experience a ... Reporting in the Sept. 16 issue of the New ...
... Center at the University of California, San Diego has ... the American College of Radiology (ACR). ... and this prestigious certificate recognizes our extraordinary effort," said ... Moores UCSD Cancer Center. "ACR leads the way toward ...
Cached Medicine News:Health News:Low-Dose Aspirin May Reduce Colon Cancer Risk 2Health News:Low-Dose Aspirin May Reduce Colon Cancer Risk 3Health News:Stress accelerates breast cancer progression in mice 2Health News:Stress accelerates breast cancer progression in mice 3Health News:Stress accelerates breast cancer progression in mice 4Health News:FDA Advisers Divided on Whether to Ban Diet Drug Meridia 2Health News:FDA Advisers Divided on Whether to Ban Diet Drug Meridia 3Health News:Autistic Children Don't Seem to Yawn 'Contagiously' 2Health News:Autistic Children Don't Seem to Yawn 'Contagiously' 3Health News:Anemia Drugs Could Pose Threat to Some Kidney Patients 2Health News:Anemia Drugs Could Pose Threat to Some Kidney Patients 3
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: